Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis

Abstract

Background Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still limited. The application of immunotherapy is a potentially beneficial new neoadjuvant treatment option for esophageal cancer. The objective of this meta-analysis is to evaluate the efficacy and safety of immunotherapy for the neoadjuvant treatment of esophageal cancer. Methods We will search Wanfang Database, SinoMed, China National Knowledge Infrastructure, Embase, Web of Science, Pubmed, and Cochrane Library for relevant articles published before July, 2021. We will also search the unpublished clinical trials of neoadjuvant immunotherapy in esophageal cancer in preprint website (such as bioRXiv and medRxiv) up to July, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy for resectable esophageal cancer. Randomized controlled trials (RCTs) will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data. Results The results of this study will provide evidence of immunotherapy using as neoadjuvant treatment for esophageal cancer. This meta-analysis will be submitted to a peer-reviewed journal seeking for publication. Conclusion The results of this study will provide a reliable basis for clinicians and patients to formulate the best pre-surgical treatment plan for resectable esophageal cancer. Systematic review registration INPLASY202120026.

Immune checkpoint inhibitors combined with antiangiogenic drugs in the treatment of unresectable locally advanced / distant metastatic esophageal squamous cell carcinoma: a systematic review protocol

“…We will use Cochran Q and I 2 statistics to assess the statistical heterogeneity between trials. When P < 0.10 or I 2 > 50%, it indicates that there is obvious heterogeneity [15] , then choose the random effect model to analyze the data, otherwise we will use the fixed effect model. If the same study results use different measurement methods, we will use the inverse variance method to calculate standardized mean difference(SMD) and 95%CI, and we will analyze the data based on the mean, standard deviation and number of participants between the intervention group and the control group to calculate the mean difference and 95%CI between the treatment group.…”

Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies

“…It is yet to be established, whether ICIs should be given in an adjuvant or neodajuvant setting. In EC patients, neoadjuvant therapy is an essential part of multimodality treatments, and several studies indicated that the effectiveness of complete surgical resection may be enhanced by incorporating an early intervention with ICIs [106][107][108]. On the other hand, adjuvant administration of ICIs was also shown to significantly improve the disease-free survival [109,110].…”

Role of drug-eluting bead bronchial arterial chemoembolisation in the treatment of non-small cell lung cancer: protocol for a meta-analysis

“…The risk of bias for each included study will be assessed independently by the same researchers using the Cochrane Handbook for Systematic Reviews of Interventions. 25 Selection, performance, detection, attrition, reporting and other biases will be used to assess the risk of bias.…”